Suppr超能文献

胰腺体尾部腺癌:辅助放疗是否有空间?

Adenocarcinoma of the body and tail of the pancreas: is there room for adjuvant radiotherapy?

作者信息

Coquard R, Ayzac L, Romestaing P, Ardiet J M, Sentenac I, Gilly F N, Braillon G, Gérard J P

机构信息

Service de Radiothérapie Oncologie, Centre Hospitalier Lyon Sud, Pierre Bénite, France.

出版信息

Tumori. 1997 Jul-Aug;83(4):740-2. doi: 10.1177/030089169708300405.

Abstract

AIMS AND BACKGROUND

Adenocarcinoma of the body and tail of the pancreas is a rare malignancy with a poor prognosis. Few long-term survivors have been reported in the literature. The role of adjuvant treatment after curative resection has not yet been assessed. This retrospective study aims to describe the patterns of failure and the survival of 10 patients treated with resection and adjuvant radiotherapy.

MATERIALS AND METHODS

From 1982 to June 1994, 10 patients with adenocarcinoma of the body and tail of the pancreas received adjuvant radiotherapy in our department. There were 4 females and 6 males, with a median age of 63 years (range, 45-77). The pT distribution was 2 pT1, 4 pT2, 4 pT3 and for pN it was 7 pN0 and 3 pN1. Four patients had stage I, 3 stage II and 3 stage III disease. All the patients underwent a resection: distal pancreatectomy in 7, partial resection of the body in 1, and total pancreatectomy in 2. Gross residual disease was present in 2 cases. Three patients received intraoperative radiotherapy up to a dose of 12-15 Gy. Postoperative radiotherapy was given in 9 patients with a dose ranging from 40 to 50 Gy (median, 45). One patient who received intraoperative radiotherapy had no postoperative radiotherapy. In 4 patients, chemotherapy with 5-fluorouracil was given during the first week of irradiation.

RESULTS

Six patients experienced a local-regional relapse and 3 developed metastases. The median survival was 21 months. The 5-year overall survival was 15%. Eight patients died of progressive disease. One patient who presented with stage I disease was alive and free of disease at 24 months from diagnosis and, interestingly, one with stage III disease was alive at 111 months. No severe treatment-related complications were observed.

CONCLUSIONS

As in carcinoma of the head of the pancreas, adjuvant radiotherapy should be considered as an adjuvant treatment of resected adenocarcinoma of the body and tail of the pancreas. Further evaluation is necessary to assess the role of intraoperative radiotherapy.

摘要

目的与背景

胰体尾腺癌是一种罕见的恶性肿瘤,预后较差。文献中报道的长期存活者很少。根治性切除术后辅助治疗的作用尚未得到评估。这项回顾性研究旨在描述10例接受切除及辅助放疗患者的失败模式和生存情况。

材料与方法

1982年至1994年6月,10例胰体尾腺癌患者在我科接受辅助放疗。其中女性4例,男性6例,中位年龄63岁(范围45 - 77岁)。pT分布为2例pT1、4例pT2、4例pT3,pN分布为7例pN0和3例pN1。4例为Ⅰ期,3例为Ⅱ期,3例为Ⅲ期疾病。所有患者均接受了手术切除:7例行胰体尾切除术,1例行胰体部分切除术,2例行全胰切除术。2例有肉眼残留病灶。3例患者接受了术中放疗,剂量达12 - 15 Gy。9例患者接受了术后放疗,剂量范围为40至50 Gy(中位剂量45 Gy)。1例接受术中放疗的患者未接受术后放疗。4例患者在放疗的第一周接受了5 - 氟尿嘧啶化疗。

结果

6例患者出现局部区域复发,3例发生转移。中位生存期为21个月。5年总生存率为15%。8例患者死于疾病进展。1例Ⅰ期疾病患者自诊断后24个月存活且无疾病,有趣的是,1例Ⅲ期疾病患者在111个月时仍存活。未观察到严重的治疗相关并发症。

结论

与胰头癌一样,辅助放疗应被视为胰体尾切除腺癌的辅助治疗。需要进一步评估以确定术中放疗的作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验